Comparison of clinical outcomes in elderly patients undergoing TAVR- a nationwide analysis

Mukunthan Murthi[1], Sujitha Velagapudi[1], Bharosa Sharma[1], Emmanuel Akuna[1], Olisa Ezegwu Kingsley[1]

[1]John H Stroger Jr Hospital of Cook County, Chicago, Illinois, USA- 60612

Mukunthan Murthi

Mukunthan.murthi@cookcountyhealth.org

Department of Internal Medicine

John H Stroger Jr Hospital of Cook County, Chicago, Illinois, USA- 60612

Sujitha Velagapudi

sujitha.velagapudi@cookcountyhealth.org

Department of Internal Medicine

John H Stroger Jr Hospital of Cook County, Chicago, Illinois, USA- 60612

Bharosa Sharma

bharosa.sharma@cookcountyhealth.org

Department of Internal Medicine

John H Stroger Jr Hospital of Cook County, Chicago, Illinois, USA- 60612

Olisa Ezegwu Kingsley

olisa.ezegwu@cookcountyhhs.org

Department of Internal Medicine

John H Stroger Jr Hospital of Cook County, Chicago, Illinois, USA- 60612

Emmanuel Akuna

emmanuel.akuna@cookcountyhhs.org

Department of Internal Medicine

John H Stroger Jr Hospital of Cook County, Chicago, Illinois, USA- 60612

Corresponding author:

Mukunthan Murthi MD

John H Stroger Jr Hospital of Cook County

Chicago, IL- 60612

Email: mukunthan338@gmail.com

Disclosures: All authors do not have any conflicts of interest to disclose

Funding: no grants, contracts, or other forms of financial support was received

Keywords

aortic stenosis, Transcatheter aortic valve replacement, elderly

Running title: Nationwide analysis of TAVR outcomes in elderly

Word count: 2,191

Introduction

Transcatheter aortic valve replacement (TAVR) is a less invasive alternative to traditional surgical aortic valve replacement (SAVR) that has been increasingly utilized in the management of aortic stenosis. Several studies have compared the outcomes of TAVR to SAVR, and studies have also compared the clinical outcomes in the elderly population. However, the comparison in outcomes of TAVR between patients more than 80 years and less than 80 years old has not been well characterized. Therefore, in this study, we sought to assess the hospital outcomes and major adverse events of TAVR in patients ≥80 years old compared to those <80 years.

Methods

We performed a retrospective observational study using the National Inpatient Sample for the year 2018. Using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10) procedure codes we identified patients who underwent TAVR. We further divided these patients into two cohorts based on age being ≥80 years and <80 years old. The primary outcomes were the comparison of in-hospital mortality and major adverse events (MAE) in patients with TAVR procedure stratified based on age. Secondary analysis included sub-groups analysis of both the cohorts and comparing those with and without MAE as well as comparison of those with MAE only in both cohorts.

Results

We identified 63,630 patients who underwent TAVR procedures from January 1 to December 31, 2018. Among them, 35, 115(55%) were ≥80 years and 28,515(45%) were <80 years of age. There was no difference in the in-hospital mortality rate (1.6% vs. 1.1%, p=0.89) and rates of MAE (23.8 vs 23.4, p=0.49) between ≥80 and <80year patients. Anemia (aOR-2.12 vs. aOR-1.93), Liver disease (aOR-1.57

vs aOR-1.48), CKD (aOR-1.34 vs. aOR-1.68), history of stroke (aOR-1.54 vs. aOR-1.46), and a higher number of comorbidities were independently associated with higher odds of MAE in both groups. Among patients ≥80, increasing age was also associated with higher MAE (aOR-1.03). In patients who had MAE, those < 80 years had higher comorbidities compared to those ≥80 years (Charlson category ≥3 - 74.5 vs 67%, p<0.001). More patients of age ≥80 years old also belonged to zip-codes with higher median income (p<0.001). On multivariate analysis of patients with MAE on both cohorts, there was no significant difference in in-hospital mortality rate (p=0.65) and length of stay (p=0.12) but total hospital charges were higher for patients less than 80 years of age (283,618 vs 300,624$, p=0.04). However, patients ≥80 years had a higher rate of pacemaker insertion compared to those < 80 years (25.1 vs 24.4%, p=0.008).

Conclusion

This study shows that in patients undergoing TAVR, the in-hospital mortality and MAE were not statistically significant between those aged ≥80 years and < 80 years. However, among subjects who experienced MAE, those < 80 years had a higher proportion of comorbidities than those ≥80 years of age. Our study also shows that for those above 80 years of age undergoing TAVR, the odds of MAE increases by 3% for each year on increasing age.

Introduction:

Aortic stenosis is the leading cause of left ventricular outflow tract obstruction, notably in the elderly. The most common causes of aortic stenosis include bicuspid valve, calcification, and rheumatic heart disease(1). About 5% of the population over 65 years of age have aortic stenosis and the percentage increases exponentially with older age. In addition, the prevalence of severe aortic stenosis also increases with age, with 3.4 to 4.3% of adults over 75 years having severe aortic stenosis (2, 3).

For many years, surgical aortic valve replacement has been the standard of care for severe symptomatic aortic stenosis until the advent of transcatheter aortic valve replacement (TAVR). TAVR has been the alternative treatment option in patients considered unsuitable for surgery(4). From the initial approval for patients with severe AS and prohibitive operative risk, it is currently utilized even for severe aortic stenosis and low-risk patients(5, 6).

Several studies have compared the outcomes of TAVR compared to Surgical aortic valve replacement (SAVR). Studies have also compared these outcomes specifically in octogenarians(7, 8) and Nonagenarians(9). However, there are limited data comparing the difference in outcomes of TAVR between patients more than 80 years and less than 80 years old. Therefore, we wanted to analyze the demographic characteristics and in-hospital outcomes after TAVR procedure in patients ≥80 years old compared to those <80 years. We also wanted to investigate the factors independently associated with major adverse events (MAE) in these groups.

Methods:

Design and Data source:

We performed a retrospective study involving adult hospitalizations undergoing the TAVR procedure in the USA in 2018. We extracted data from the National Inpatient Sample for the year 2018. The NIS is the largest publicly available all-payer inpatient admission database in the USA. It is developed by the

Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases (SID). This dataset contains discharge information for over 7 million discharges annually with data stratified as a weighted sample. Discharge weights were calculated using post-stratification on hospital characteristics (census region, urban-rural location, teaching status, bed size, and hospital control) and patient characteristics (sex and five age groups [0, 1-17, 18-44, 45-64, and 65 and older]). Since the NIS does not include individual patient identifiers it does not require approval from the Cook County Health Institutional Review Board. This manuscript conforms with the STROBE statement for observational studies.

Study population and variables:

We identified patients who underwent TAVR procedure in the year 2018 using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD□10□CM) procedure codes (Supplemental Table 1). We further divided these patients into two groups based on age being ≥80 years and <80 years old. The NIS dataset includes variables on patient demographics, including age, gender, race, median household income, and type of insurance. It also contains hospital-level data including hospital bed size, teaching status, and location. Comorbidities were identified using ICD-10 codes as well as Sundararajan's adaptation of the modified Deyo's Charlson comorbidity index (CCI)(10).

Measures of Outcome:

The primary outcomes were the comparison of mortality and in-hospital major adverse events (MAE) in patients with TAVR procedure stratified based on age. We included post-procedural hemorrhage, cardiac complications, acute kidney injury (AKI), stroke, and TIA as MAE. Secondary outcomes included rates of pacemaker insertion, assessment of the mean length of hospital stay (LOS), total hospital charges (THC), and independent predictors of MAE.

Statistical analysis

We analyzed the data using Stata® Version 16 software (StataCorp, Texas, USA). We conducted all the analyses using the weighted samples for national estimates in accordance with HCUP guidelines. We calculated comorbidities as proportions of the cohorts and used the Chi-square test for comparison. We used univariate regression to identify variables affecting primary outcomes. We included those variables having a p-value < 0.1 in the final multivariate regression model. Variables identified to be significant by literature review were also forced into the model. Subsequently, we ran a multivariate cox regression analysis to identify independent predictors of MAE with p-values <0.05 set as the threshold for statistical significance. For MAE analysis in all TAVR patients, these variables included age ≥80 years, Gender, Race, Zip-code wise median household income, region of hospital, insurance status, Charlson comorbidity category, COPD, previous stroke, Obesity, Diabetes mellitus, peripheral vascular disease, Liver disease, smoking history, and anemia. For MAE analysis in patients ≥80, the variables used in the multivariate analysis include age, Gender, Race, Charlson comorbidity category, COPD, previous stroke, hypertension, diabetes mellitus, heart failure, chronic kidney disease, Liver disease, hemodialysis, smoking history, and anemia. For MAE analysis for patients <80, variables for multivariate analysis included age, Gender, Race, Charlson comorbidity category, insurance status, COPD, previous stroke, hypertension, diabetes mellitus, heart failure, chronic kidney disease, Liver disease, smoking history, and anemia.

Results:

We identified 63,630 patients who underwent the TAVR procedure from January 1 to December 31, 2018. Among them, 35, 115(55%) were ≥80 years and 28,515(45%) were <80 years of age. Among patients ≥80 and <80 years of age, the mean age was 85(SE ±0.04) vs 71 years (SE±0.11) (p<0.001) and the proportion of females were 48% vs 44% respectively (p=0.0002). European whites formed the major

proportion of both groups. The number of patients with ≥3 comorbidities was higher in those <80 years old (51.2 vs 59.6%, p<0.001). A larger proportion of patients <80 years old were privately insured compared to those ≥80 years old (3.8 vs 12%, p>0.001). All other baseline characteristics are shown in Table 1 and Figure 1.

In-hospital outcomes:

Comparison of TAVR patients ≥80 years vs < 80 years:

The in-hospital mortality rate for patients ≥80 years and < 80 years of age was 1.6% and 1.1% respectively (p=0.89). The rates of MAE were not different in patients ≥80 years of age compared to those <80 years (23.8 vs 23.4, p=0.49). There were no significant differences in the length of stay (3.7 vs 4.2 days, p=0.21) and total hospital charges ($214,919 vs $220,681, p=0.1) between patients ≥80 years and < 80 years of age (Table 2). On multivariate regression analysis, age ≥80 years was not independently associated with increased MAE in TAVR patients. Figure 2 shows the independent factors associated with MAE.

Comparison of TAVR patients ≥80 years with and without MAE:

The mean age for patients with and without MAE was 85.5(SE±0.08) vs 85.1(SE±0.04) respectively (<0.001). Patients with MAE had significantly higher comorbidities compared to those without MAE (Table 3). The in-hospital mortality rate (5.7 vs 0.3%, p<0.001), length of stay (7.2 vs 2.6 days, p<0.001) and total hospital charges (283,618 vs 193,473$, p<0.001) were significantly higher in patients ≥80 years with MAE. Anemia (aOR-2.12), Liver disease (aOR-1.57), CKD (aOR-1.34), history of stroke (aOR-1.54) and higher number of comorbidities (aOR-1.97) were independently associated with higher odds of MAE (Figure 3). Increasing age was also associated with worse outcomes (aOR-1.03).

Comparison of TAVR patients <80 years with and without MAE:

The mean age for patients with and without MAE was 71.2(SE±0.19) vs 71.4(SE±0.13) respectively (<0.001). The proportion of patients with comorbidities was significantly higher among those who experienced MAE compared to those without MAE (Table 3). Patients with MAE had a higher proportion of Medicaid insurance (4.4 vs 2.6%, p=0.008). Similar to patients age ≥80 years, the mortality rate (4.3 vs 0.2%, p<0.001), length of stay (8.7 vs 2.8 days, p<0.001) and total hospital charges (300,624 vs 196,224, p<0.001) were significantly higher in patients <80 years with MAE (Table 3). Anemia (aOR-1.93), liver disease(aOR-1.48), CKD (aOR-1.68), history of stroke(aOR-1.46), multiple comorbidities were independently associated with higher odds of MAE. African American (aOR-0.69) race was associated with lower odds of MAE (Figure 4).

Comparison of TAVR patients with MAE and age ≥80 years vs < 80 years:

Among patients with in-hospital MAE, those < 80 years had higher comorbidities compared to those ≥80 years (Charlson category ≥3 - 74.5 vs 67%, p<0.001). More patients of age ≥80 years old also belonged to zip-codes with higher median income (p<0.001). On multivariate analysis, the was no significant difference in in-hospital mortality rate (5.7 vs 4.3%, p=0.65) and length of stay (7.2 vs 8.7 days, p=0.12) among patients aged ≥80 years compared to those < 80 years. The total hospital charges were higher for patients less than 80 years of age ($283,618 vs $300,624, p=0.04). Those ≥80 years had a higher rate of pacemaker insertion compared to those < 80 years (25.1 vs 24.4%, p=0.008).

Discussion:

Our study shows that in patients undergoing TAVR there was no significant difference in in-hospital mortality and MAE between those age ≥80 years and < 80 years. Among subjects who experienced MAE, those < 80 years had a higher proportion of comorbidities compared to those ≥80 years old. Anemia, CKD, Liver disease, presence of three or more comorbidities and previous stroke were associated with higher odds of MAE in both groups.

Irrespective of the indication for admission, studies have shown increased in-hospital complication rates associated with older age resulting in worse outcomes (11). TAVR is a relatively safe procedure even in nonagenarians (12). Multiple studies have been performed comparing TAVR to SAVR in the older population. Siyuan et al showed that TAVR might be preferred to SAVR in high-risk octogenarians as they had a shorter length of stay, lower incidence of AKI, bleeding, and cardiogenic complications(7). The study by Yamamoto et al showed no significant differences in mortality in patients undergoing TAVR stratified into 3 groups (80 to 84, 85 to 89 and ≥90 years old). These results corroborate findings from our study showing no significant difference in in-hospital outcomes undergoing TAVR in patients ≥80 years and < 80 years old(9). However, our data does show a small increase (3%/year) in odds of MAE with increasing age in patients ≥80 years undergoing TAVR.

Our study identified that anemia and liver disease were associated with higher odds of in-hospital MAE in all sub-groups. Anemia patients ≥80 years old had marginally higher odds of MAE compared to those <80(a0R-2.12 vs 1.93). Anemia has been reported to be present in 30% of the patients with AS(13). Several studies have shown that anemia has been associated with worse short and long-term outcomes in patients undergoing TAVR(14-19). A meta-analysis by Kanjanahattakij et al showed increased long-term outcomes but no change in short-term mortality(20).

Our data also showed that liver disease was associated with higher odds of MAE in both ≥80 years and < 80 years old. The older subgroup had lower prevalence but slightly higher odds (a0R-1.48 vs 1.57) of MAE with liver disease. previous studies have shown that liver disease is associated with higher mortality and morbidity in patients undergoing TAVR. A multicenter study by Tirado-Conte et al showed that long-term non-cardiac mortality was higher in those with Liver disease, especially those with Child B and C cirrhosis, but in-hospital mortality (7%) was not affected by liver disease(21). In their retrospective study of 640 patients, Wendt et al showed that patients with Liver cirrhosis undergoing TAVR had an in-hospital mortality rate of 36.4%(22). The possible variation could be due to the difference in severity of liver disease which cannot be assessed from the NIS database.

Our study data shows that TAVR patients < 80 years old have a higher comorbidity burden compared to age ≥80 years, except for stroke and PVD. The possible explanation for this could be the wide use of risk stratification tools for patients undergoing TAVR, namely the STS (Society of Thoracic Surgeons) and euro SCORE II models. These models place older patients with AS and multiple comorbidities at unacceptably higher risk of adverse outcomes, thereby resulting in reduced TAVR rates in this population(23, 24).

Pacemaker insertion is a common procedure-related complication of TAVR(25). The meta-analysis by Ullah et al showed that male gender, baseline AV conduction abnormalities and intra-operative AV block are associated with higher odds of pacemaker insertion in TAVR patients(26). The study also showed no significant difference in pacemaker insertion rates in patients ≥80 and <80 years of age. While the main cohort analysis from our data showed similar trends, the subgroup analysis is significantly different. Patients with MAE had 10 to 20 times higher rates of pacemaker insertion in our study likely secondary to cardiac complications. Additionally, patients ≥80 years with MAE had higher pacemaker insertion rates compared to those <80 years with MAE. Although a causal relationship cannot be established from our study, further studies are required to see if in-hospital MAE can be predictors of pacemaker insertion after TAVR.

Limitations:

Our study has several limitations. Firstly, data from the NIS is subject to biases associated with retrospective studies. Given that data is interpreted from NIS based on ICD codes, errors with coding may affect data accuracy. Additionally, due to the inherent design of NIS, long-term follow-up of outcomes is not possible. Since laboratory and pharmacological data are unavailable, utilization and comparison with STS and EUROSCORE were not feasible. Furthermore, comparing the rates of pacemaker insertion cannot be done since most studies report 30-day rates of pacemaker insertion rather than in-hospital rates.

Finally, the NIS does not include information about the severity of the diagnosis at the time of admission. For example, the NYHA stage of heart failure or stage of CKD cannot be assessed.

References:

1. Grimard BH, Safford RE, Burns EL. Aortic Stenosis: Diagnosis and Treatment. Am Fam Physician. 2016;93(5):371-8.
2. Osnabrugge RLJ, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, LeReun CM, et al. Aortic Stenosis in the Elderly: Disease Prevalence and Number of Candidates for Transcatheter Aortic Valve Replacement: A Meta-Analysis and Modeling Study. Journal of the American College of Cardiology. 2013;62(11):1002-12.
3. Danielsen R, Aspelund T, Harris TB, Gudnason V. The prevalence of aortic stenosis in the elderly in Iceland and predictions for the coming decades: the AGES-Reykjavík study. Int J Cardiol. 2014;176(3):916-22.
4. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187-98.
5. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597-607.
6. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016;374(17):1609-20.
7. Sheng SP, Strassle PD, Arora S, Kolte D, Ramm CJ, Sitammagari K, et al. In‐Hospital Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Octogenarians. Journal of the American Heart Association. 2019;8(2):e011206.
8. Hirji SA, Ramirez-Del Val F, Kolkailah AA, Ejiofor JI, McGurk S, Chowdhury R, et al. Outcomes of surgical and transcatheter aortic valve replacement in the octogenarians-surgery still the gold standard? Ann Cardiothorac Surg. 2017;6(5):453-62.
9. Yamamoto M, Mouillet G, Meguro K, Gilard M, Laskar M, Eltchaninoff H, et al. Clinical Results of Transcatheter Aortic Valve Implantation in Octogenarians and Nonagenarians: Insights From the FRANCE-2 Registry. The Annals of Thoracic Surgery. 2014;97(1):29-36.
10. Sundararajan V, Quan H, Halfon P, Fushimi K, Luthi JC, Burnand B, et al. Cross-national comparative performance of three versions of the ICD-10 Charlson index. Med Care. 2007;45(12):1210-5.
11. Flacker JM. What Is A Geriatric Syndrome Anyway? Journal of the American Geriatrics Society. 2003;51(4):574-6.
12. Mentias A, Saad M, Desai MY, Horwitz PA, Rossen JD, Panaich S, et al. Temporal Trends and Clinical Outcomes of Transcatheter Aortic Valve Replacement in Nonagenarians. Journal of the American Heart Association. 2019;8(21):e013685.
13. Tjahjadi C, Wee Y, Hay K, Tesar P, Clarke A, Walters DL, et al. Heyde syndrome revisited: anaemia and aortic stenosis. Intern Med J. 2017;47(7):814-8.
14. Arai T, Morice M-C, O'Connor SA, Yamamoto M, Eltchaninoff H, Leguerrier A, et al. Impact of pre- and post-procedural anemia on the incidence of acute kidney injury and 1-year mortality in patients undergoing transcatheter aortic valve implantation (from the French Aortic National CoreValve and Edwards 2 [FRANCE 2] Registry). Catheterization and Cardiovascular Interventions. 2015;85(7):1231-9.

15. DeLarochellière H, Urena M, Amat-Santos IJ, Ribeiro HB, Allende R, Laflamme L, et al. Effect on outcomes and exercise performance of anemia in patients with aortic stenosis who underwent transcatheter aortic valve replacement. Am J Cardiol. 2015;115(4):472-9.
16. Hellhammer K, Zeus T, Verde PE, Veulemanns V, Kahlstadt L, Wolff G, et al. Red cell distribution width in anemic patients undergoing transcatheter aortic valve implantation. World J Cardiol. 2016;8(2):220-30.
17. Nuis RJ, Sinning JM, Rodés-Cabau J, Gotzmann M, van Garsse L, Kefer J, et al. Prevalence, factors associated with, and prognostic effects of preoperative anemia on short- and long-term mortality in patients undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2013;6(6):625-34.
18. Rheude T, Pellegrini C, Michel J, Trenkwalder T, Mayr NP, Kessler T, et al. Prognostic impact of anemia and iron-deficiency anemia in a contemporary cohort of patients undergoing transcatheter aortic valve implantation. Int J Cardiol. 2017;244:93-9.
19. Seiffert M, Conradi L, Gutwein A, Schön G, Deuschl F, Schofer N, et al. Baseline anemia and its impact on midterm outcome after transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2017;89(1):E44-e52.
20. Kanjanahattakij N, Rattanawong P, Krishnamoorthy P, Sirinvaravong N, Chongsathidkiet P, Lapumnuaypol K, et al. Anaemia and mortality in patients with transcatheter aortic valve replacement: a systematic review and meta-analysis. Acta Cardiol. 2019;74(5):386-92.
21. Tirado-Conte G, Rodés-Cabau J, Rodríguez-Olivares R, Barbanti M, Lhermusier T, Amat-Santos I, et al. Clinical Outcomes and Prognosis Markers of Patients With Liver Disease Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions. 2018;11(3):e005727.
22. Wendt D, Kahlert P, Canbay A, Knipp S, Thoenes M, Cremer G, et al. Impact of Liver Indicators on Clinical Outcome in Patients Undergoing Transcatheter Aortic Valve Implantation. The Annals of Thoracic Surgery. 2017;104(4):1357-64.
23. Surgeons SoT. STS Short-Term Risk Calculator: The Annals of Thoracic Surgery; 2018 [Available from: https://www.sts.org/resources/risk-calculator.
24. Group ES. euroSCORE II INTERACTIVE CALCULATOR 2011 [Available from: http://www.euroscore.org/calc.html.
25. Huang HD, Mansour M. Pacemaker Implantation After Transcatheter Aortic Valve Replacement: A Necessary Evil Perhaps But Are We Making Progress? Journal of the American Heart Association. 2020;9(9):e016700.
26. Ullah W, Zahid S, Zaidi SR, Sarvepalli D, Haq S, Roomi S, et al. Predictors of Permanent Pacemaker Implantation in Patients Undergoing Transcatheter Aortic Valve Replacement ‐ A Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 2021;10(14):e020906.

Figures:

Figure 1: Graph showing prevalence of comorbidities among TAVR patients ≥80 years vs < 80 years

Figure 2: Independent factors associated with MAE in patients undergoing TAVR. PVD-Peripheral vascular Disease

Figure 3: Independent factors associated with MAE in patients ≥80 years undergoing TAVR. CKD: Chronic Kidney disease

Figure 4: Independent factors associated with MAE in patients <80 years undergoing TAVR. CKD: Chronic Kidney disease.

Table 1: Clinical and demographic characteristics of TAVR patients.

Patient characteristics	≥80	<80	P value
Subjects (n,%)	35,115(55%)	28,515(44%)	
Mean age (in years) (SE)	85±0.04	71±0.11	<0.001
Female (%)	48	44	0.0002
***Race* (%)**			<0.001
White	88	83	
Black	3	6.2	
Hispanic	5	6.7	
Other	4	4	
***Charlson Category (No. of comorbidities)* (%)**			<0.001
0	7.4	5	
1	20.6	15.6	
2	20.6	19.6	
≥3	51.2	59.6	
***Zip-code wise median income (in $)* (%)**			<0.001
1 - 45,999	18.3	24.7	
46,000 - 58,999	25.2	25.9	
59,000 - 78,999	27.6	26.7	
79,000+	28.8	23.1	
***Insurance* (%)**			<0.001
Medicare	95.5	84	
Medicaid	0.3	3	
Private	3.8	12	
Other	0.1	0.7	
***Hospital region* (%)**			<0.001
Northeast	23.2	19.1	

Midwest	22	22.4	
South	32.6	38	
West	21.9	20.3	
***Hospital Bed-size* (%)**			0.17
Small	6.9	7.6	
Medium	21	19.5	
Large	72	72.8	
***Location/teaching status of hospital* (%)**			0.51
Rural	0.8	0.6	
Urban non-teaching	9.1	8.8	
Urban teaching	90	90.5	
***Comorbidities* (%)**			
COPD	19.4	28.2	<0.001
Stroke	15	11.8	<0.001
Hypertension	17.9	17.9	0.97
PVD	9.6	8.1	0.003
Diabetes	28.9	44.6	<0.001
Obese	10.9	27.6	<0.001
Heart failure	72.7	73.7	0.25
CKD	35.8	34.9	0.32
Liver disease	1.6	5.7	<0.001
Hemodialysis	1.2	5	<0.001
Smoking	34.8	36.8	0.02
Anemia	32.1	33.8	0.04

Table 2: In hospital outcomes and Major adverse events in TAVR patients stratified by age

Variable (%)	≥80 years age	<80 years age	p- value[#]
MAE	23.8	23.4	0.49
Post procedural hemorrhage	1.7	1.7	0.23
Cardiac complications	13.2	12.9	0.35
AKI	10.3	11.3	0.55
Stroke & TIA	4.2	3.5	0.79
Pacemaker insertion	7.4	6.5	0.189
Died	570(1.6%)	335(1.1%)	0.89
Length of stay (in days)	3.7(CI 3.5-3.8)	4.2 (CI 4-4.4)	0.21
Total hospital discharges (in $)	214,919	220,681	0.1

[#]Multivariate analysis

MAE= Major adverse events, TIA= Transient ischemic attack, AKI= Acute kidney injury

Table 3:

Patient characteristics	≥80 MAE	≥80 No MAE	P value	<80 MAE	<80 No MAE	P value	P value *

Mean age (in years) (SE)	85.5±0.08	85.1±0.04	*<0.001*	71.2±0.19	71.4±0.13	*<0.001*	<0.001
Female (%)	47.3	48.1	*0.55*	44.6	44.7	*0.92*	0.13
***Race* (%)**			*0.31*			*0.10*	0.01
White	87.6	88.2		82.1	83.4		
Black	3.3	3.1		6.2	6.3		
Hispanic	6.1	4.8		1.9	6.1		
Other	2.7	3.1		3.3	3.7		
***Charlson Category (No. of comorbidities)* (%)**			*<0.001*			*<0.001*	<0.001
0	3.9	8.5		1.9	6		
1	13.5	22.9		8.6	17.8		
2	15.4	22.2		14.8	21.1		
≥3	67	46.2		74.5	55		
***Zip-code wise median income (in $)* (%)**			*0.46*			*0.68*	<0.001
1 - 45,999							
46,000 - 58,999	17.7	18.5		23.1	24.4		
59,000 - 78,999	24	25.5		27	25.6		
79,000+	28.4	27.3		26.7	26.7		
	29.7	28.5		23	23.2		
***Co-morbidities* (%)**							
COPD	21.8	18.7	*0.006*	31.7	27.1	*0.0006*	<0.001
Stroke	19.8	13.4	*<0.001*	15.9	10.6	*<0.001*	0.008
Hypertension	12.3	19.6	*<0.001*	12.1	19.7	*<0.001*	0.87
PVD	9.8	9.5	*0.81*	8.8	7.9	*0.28*	0.37
Diabetes	33.9	27.3	*<0.001*	48.9	43.2	*0.0003*	<0.001
Obese	11.1	10.9	*0.81*	27.4	27.7	*0.81*	<0.001
Heart failure	78.6	70.9	*<0.001*	79.5	71.9	*<0.001*	0.55
CKD	49.6	31.5	*<0.001*	50.6	30.1	*<0.001*	0.59
Liver disease	2.6	1.3	*0.0002*	8.5	4.8	*<0.001*	<0.001
Hemodialysis	1.7	1	*0.01*	4.2	5.2	*0.15*	<0.001
Smoking	32.9	35.4	*0.09*	32.4	38.1	*0.0002*	0.77
Anemia	48.2	27	*<0.001*	49.3	29.1	*<0.001*	0.55
***Insurance* (%)**			*0.42*			*0.008*	<0.001
Medicare	95.8	95.4		82.8	84.5		
Medicaid	0.2	0.4		4.4	2.6		
Private	3.6	3.9		11.9	12.1		
Other	0.3	0.1		0.6	0.7		
***Hospital region* (%)**			*0.76*			*0.98*	0.004
Northeast	24.3	22.9		18.9	19.2		
Midwest	22.3	22		22.1	22.5		
South	32	32		38.4	37.8		
West	21.2	22.1		20.4	20.3		
***Hospital Bed-size* (%)**			*0.93*			*0.08*	0.19
Small	6.6	6.9		6.4	8		
Medium	20.9	20.9		18.1	19.8		
Large	72.3	72		75.4	72.1		

Location/teaching status of hospital **(%)**			*0.88*			*0.06*	*0.07*
Rural	0.7	0.8		0.2	0.7		
Urban non-teaching	9	9.1		8.1	9		
Urban teaching	90.2	90		91.6	90.2		
Pacemaker insertion	25.1	1.9	*<0.001#*	24.4	1	*<0.001#*	*0.008#*
Died (%)	5.7	0.3	*<0.001#*	4.3	0.2	*<0.001#*	*0.65#*
Length of stay (in days)	7.2	2.6	*<0.001#*	8.7	2.8	*<0.001#*	*0.12#*
Total charges ($)	283,618	193,473	*<0.001#*	300,624	196,224	*<0.001#*	*0.04#*

*P value comparing subjects ≥80 and <80 years old with MAE.


(In %)
80
70
60
50
40
30
20
10
0
19.4
28.2
15
11.8
17.9
17.9
9.6
8.1
28.9
44.6
10.9
27.6
72.7
73.7
35.8
34.9
1.6
5.7
1.2
5
34.8
36.8
32.1
33.8
COPD
Stroke
Hypertension
PVD
Diabetes
Obese
Heart failure
CKD
Liver disease
Hemodialysis
Smoking
Anemia
≥80
<80


aOR(CI), p-value
Anemia
2.1(1.9-2.32),<0.001
Smoking history
0.79(0.71-0.89),<0.001
Liver Disease
1.43 (1.12-1.82)0.003
PVD
0.83 (0.71-0.98),0.024
Previous stroke
1.52(1.35-1.72),<0.001
Medicaid Insurance
1.56(1.11-2.17),0.009
Charlson comorbidities≥3
3.12(2.47-3.93),<0.001
Charlson comorbidities 2
1.6(1.26-2.05),<0.001
Charlson comorbidities 1
1.34(1.03-1.73),0.024
Female
0.95(0.87-1.04),0.354
Age ≥80
0.95(0.82-1.09),0.495
0
1
2
3
4
5


aOR(CI), p-value
Anemia
2.12(1.87-2.41), <0.001
Smoking History
0.83(0.73-0.95),0.011
Liver disease
1.57(1.03-2.41),0.035
CKD
1.34(1.13-1.59),0.001
Previous stroke
1.54(1.32-1.81),<0.001
Charlson comorbidities≥3
1.97(1.42-2.74),<0.001
Female
0.96(0.85-1.08),0.58
Age
1.03(1.01-1.05),<0.001
0
0.5
1
1.5
2
2.5
3


aOR(CI), p-value
Anemia
1.93(1.68-2.23),<0.001
Smoking History
0.76(0.66-0.88),<0.001
Liver disease
1.48(1..1-1.99),0.009
CKD
1.68(1.41-2), <0.001
Previous stroke
1.46(1.22-1.76),<0.001
Charlson comorbidities≥3
2.64(1.58-4.43),<0.001
Charlson comorbidities 2
1.92(1.15-3.22),<0.001
African American
0.69(0.53-0.91),0.008
Female
0.98(0.86-1.11),0.78
Age
1(0.99-1.01),0.91
0
1
2
3
4
5